WO2019155396A1 - Microsphères à libération prolongée à faible éclatement initial et leurs procédés de préparation - Google Patents

Microsphères à libération prolongée à faible éclatement initial et leurs procédés de préparation Download PDF

Info

Publication number
WO2019155396A1
WO2019155396A1 PCT/IB2019/050987 IB2019050987W WO2019155396A1 WO 2019155396 A1 WO2019155396 A1 WO 2019155396A1 IB 2019050987 W IB2019050987 W IB 2019050987W WO 2019155396 A1 WO2019155396 A1 WO 2019155396A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
microspheres
octreotide
acid
less
Prior art date
Application number
PCT/IB2019/050987
Other languages
English (en)
Inventor
Dhiraj Kumar CHOPRA
Arijit MAJUMDER
Harshal BHAGWATWAR
Jeroen VAN VUGHT
Rudolf Verrijk
Original Assignee
Dr. Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited
Publication of WO2019155396A1 publication Critical patent/WO2019155396A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Definitions

  • the present invention relates to biodegradable polymer based sustained release microsphere compositions of the active agent.
  • the present invention provides sustained release microspheres with low initial burst of the active agent and methods of preparation of such compositions.
  • compositions containing biologically active agents in combination with biodegradable and biocompatible polymers are being increasingly used as drug delivery systems to provide sustained or delayed release of drugs.
  • the compositions are available in various injectable depot forms including liquid forms, solid implants, microspheres, microcapsules and microparticles.
  • Octreotide is a long acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.
  • Octreotide is known chemically as L-cysteinamide, D- phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N- [2 -hydroxy- 1 - (hydroxymethyl)propyl]-, cyclic(2 7)-disulfide; [R— (R*,R*)].
  • the commercially available Sandostatin LAR formulation meant for sustained release of Octreotide acetate, which is approved for the treatment of long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
  • the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal (Acromegaly), long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors (Vasoactive Intestinal Peptide Tumors - VIPomas).
  • US20120021018A1 describes the process of preparation of sustained release Octreotide formulations with low initial burst release by means of addition of acetic acid at a certain concentration in the dispersed phase and certain concentration of the poly (D, L-lactide-co- glycolide) polymer in the dispersed phase.
  • the process described here in this application is preparing the dispersed phase by combining polymer, dichloromethane (DCM), Octreotide, methanol and acetic acid; dissolving Polyvinyl alcohol (PVA) in water to form continuous phase; mixing the both phases to form microspheres suspension. Removing DCM, acetic acid, methanol and PVA from microspheres suspension; removing the residual solvents by means of washing.
  • DCM dichloromethane
  • PVA Polyvinyl alcohol
  • US8343513 patent describes sustained release formulation comprising the biodegradable polymer, where in the prevention of the molecular weight reduction of the polymer in a polymer solution containing nucleophilic compounds is by means of a polymer having an acid number of at least 13 and but not greater than 30; further with an acid additive. Further it describes the reduction or elimination of peptide polymer impurities in the polymer solutions. Further it relates to GnRH analogue and polymer containing solutions capable of forming stable, filter sterilizable and non- gelling solutions
  • WO20160161296A1 patent application describes an improved stable injectable composition for controlled release drug delivery with less impurities and process of preparation of the same by using a) lactate-based polymer having a weight average molecular weight between 5,000 and 50,000 Dalton, an acid number of less than 3 mgKOH/g and the content of residual lactide monomers in the lactate -based polymer of less than about 0.3% by weight; b) a pharmaceutically acceptable organic solvent; and c) a active substance or a salt thereof that contains an amino acid serine in the molecular structure that is capable of reacting with lactide monomer to form a conjugate, with the proviso that no acid additive is added in producing the composition, and the composition reduces the formation of the conjugate.
  • initial burst is one of the major challenges in drug- encapsulated or peptide-encapsulated microparticle or microspheres systems.
  • Initial burst release of active agent is not always detrimental, excessive drug release in the burst phase may be toxic, and irregularity in the amount of drug released.
  • sustained release microspheres compositions with low initial burst while meeting the required release profiles and required duration and process of preparation of such microsphere compositions. Therefore, it is still desirable to have an improved process for preparation of sustained release microspheres with low initial burst of the active agent; particularly the process is simple, feasible, scalable to commercial scale, commercially economically viable.
  • the present invention relates to sustained release microspheres with low initial burst of the active agent.
  • the present invention also provides process of preparation of such compositions
  • microspheres for sustained release of an active agent with a low initial burst comprises biodegradable polymer having an acid number of less than or equal to 10 mgKOH/g.
  • an injectable microsphere composition for sustained release of active agent with a low initial burst comprises: a biodegradable polymer having an acid number of less than or equal to 10 mgKOH/g, an active agent and one or more pharmaceutically acceptable carriers.
  • the biodegradable polymer is lactate based polymer.
  • the lactate based polymer is poly (D, L-lactide-co-glycolide) polymer (PLGA).
  • PLGA polymer is PLGA glucose star polymer.
  • preferred active agents are peptides and their pharmaceutically acceptable salts thereof and most preferred active agent is Octreotide or its pharmaceutically acceptable salts thereof.
  • Octreotide acetate is one of the preferred active agents of the present invention.
  • injectable microsphere composition for sustained release of Octreotide acetate with a low initial burst comprises: (poly (D, L-lactide-co-glycolide) glucose star polymer (PLGA glucose star polymer) having an acid number of less than or equal to 10 mgKOH/g.
  • injectable microsphere compositions for sustained release of Octreotide acetate with a low initial burst comprises: (poly (D, L-lactide-co-glycolide) glucose star polymer (PLGA glucose star polymer) having an acid number of less than or equal to 10 mgKOH/g, Octreotide acetate and pharmaceutically acceptable carriers.
  • Another aspect of the present invention provides a method for preparing sustained release microspheres with low initial burst of the active agent comprises lactate based polymer having an acid number of less than or equal to 10 mgKOH/g.
  • the microspheres of the present invention are prepared by co-acervation phase separation technique.
  • a process for preparing microspheres for sustained release of an active agent with a low initial burst comprises:
  • a process for preparing microspheres for sustained release of Octreotide acetate with a low initial burst comprises:
  • a method for preparing sustained release microspheres with low initial burst of the active agent comprises:
  • a method for preparing sustained release microspheres with low initial burst of the Octreotide acetate comprises:
  • a method for preparing sustained release microspheres with low initial burst of the active agent comprises:
  • active agent is dissolved in polar solvent to form drug solution
  • microsphere suspension e) mixing with hardening agent to the co-acervates to form a microsphere suspension f) filtering microspheres followed by washing and drying of microspheres to get the finished microspheres.
  • a method for preparing sustained release microspheres with low initial burst of the Octreotide acetate comprises:
  • a method for preparing sustained release microspheres with low initial burst of the Octreotide acetate comprises:
  • microsphere suspension e) mixing with hardening agent to the co-acervates to form a microsphere suspension f) filtering microspheres followed by washing and drying of microspheres to get the finished microspheres.
  • the concentration (in % weight) of the alcoholic solvent in the drug polymer combined phase is less than about 10%. In a preferred embodiment, the concentration of the alcoholic solvent is less than about 9% or less than about 8% or less than about 7% or less than about 6% or less than about 5% or less than about 4 % or less than about 3% or less than about 2% or less than about 1%.
  • the acid number of the polymer is less than or equal to 10 mgKOH/g. According to another embodiment of present invention, the acid number of the polymer is less than or equal to 5 mgKOH/g. According to another embodiment of present invention, the acid number of the polymer is less than or equal to 4 mgKOH/g. In other embodiment, the acid number of the polymer is less than or equal to 3 mgKOH/g. In other embodiment the acid number of the polymer is less than or equal to 2 mgKOH/g.
  • the PLGA glucose star polymer having a molar ratio of lactide to glycolide ranging from 90:10 to 10:90, preferably from 80:20 to 20:80, more preferably 75 :25 to 25:75 and most preferably 40:60 to 60:40.
  • the lactide to glycolide molar ratio of the polymer is 50:50.
  • the lactate based polymer having a weight average molecular weight range is between 5,000 - 500,000 Daltons. In a preferred embodiment, the weight average molecular weight of the polymer ranges between 30,000 - 60,000 Daltons
  • the lactate based polymer having a residual monomer content (in % weight) of less than or equal to about 2.0 %. In a preferred embodiment, the residual monomer content is less than or equal to about 1.0%. In a most preferred embodiment, the residual monomer content of the polymer is less than or equal to 0.1 %
  • the lacate based polymer having an inherent viscosity (IV) in the range of 0.3 - 0.7 dL/g in chloroform. In a preferred embodiment, the IV of the polymer is 0.40 - 0.60 dL/g in chloroform. In another embodiment, the IV of the polymer is 0.42 - 0.52 dL/g in chloroform.
  • IV inherent viscosity
  • the drug loading in the microspheres is less than or equal to 10% by weight. In a preferred embodiment, the drug loading in the microspheres is ranging from 3% to 5% by weight.
  • the drug: polymer ratio in the finished microspheres is ranges about 1 :10 to 1 :30. In a preferred embodiment, the drug: polymer ration is about 1 :15 to 1 :20.
  • the weight % of the polymer in the finished microspheres is about 50% to 90%. In a preferred embodiment, the % of the polymer is about 60% to 80%
  • the particle size of the microspheres ranges from 1 to 250 microns, preferably 10 to 200 microns, most preferably 10 to 130 microns in diameter.
  • the D50 of the microspheres ranges from 10-200 microns, preferably 20-150 microns.
  • the concentration (in % weight) of the said polymer in said drug polymer combined phase ranges from about 2% to about 15%. In a preferred embodiment, the said concentration is about 3% to about 10%. According to any embodiment of the present invention, the concentration of said Active agent in the drug polymer combined phase ranges from about 0.1% to about 5%. In a preferred embodiment, the said concentration of the drug ranges from about 0.1 % to 1%.
  • the drug: polymer ratio in the drug polymer combined phase is ranges about 1 :5 to about 1 :50. In a preferred embodiment, the ratio is about 1 :10 to 1 :20.
  • the acid number of the PLGA glucose star polymer is less than or equal to 10 mgKOH/g.
  • the pharmaceutically acceptable carrier comprises an anti-agglomerating agent, viscosity enhancing agent, surfactant and diluent
  • the pharmaceutically acceptable carrier comprises mannitol, sodium CMC, Poloxamer 188 and water for injection.
  • Sustained release microspheres of the present invention are administered by IM or SC administration.
  • microspheres of the present invention are administered by IM administration.
  • Microspheres of the present invention are filled in to the vials or ampoules, and these microspheres are to be added to vehicle before administration. These microspheres when injected, delivers active agent for a period of at least one month.
  • Octreotide microspheres is used for the treatment of acromegaly, long term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors (Vasoactive Intestinal Peptide Tumors - VIPomas).
  • Figure 1 provides a graphical representation of the effect of acid number on the initial burst release, represented as percentage of Octreotide released from the sustained release microspheres in a dissolution medium with respect to time
  • Figure 2 provides the graphical representation of the one batch full IVR data represented as percentage of Octreotide release from the microspheres with respect to time
  • aspects of the present invention relate to sustained release microspheres with low initial burst of the active agent.
  • the present invention also provides methods of preparation of such compositions
  • the polymeric compositions of the present invention comprise an active agent, a biodegradable polymer and one or more pharmaceutically acceptable carriers.
  • the polymeric compositions may be in the forms of microparticles, microspheres, microcapsules, microgranules or solid implants by removing the organic solvent prepared in vitro. These compositions can be administered by methods known in the art, examples include but not limited to injection or surgical intervention or oral or transdermal or topical etc.
  • microsphere, microparticle and microcapsule can be used interchangeably regarding the invention and encapsulation of the active agent by the polymer.
  • Active agent is dispersed in a matrix of the PLGA polymer.
  • microsphere is used throughout this disclosure.
  • injectable compositions of the present invention can be administered by different routes and is very well known in the art, for example subcutaneous, Intravenous, intramuscular, intra-arterial, intrathecal etc. Alternatively, it may be in the forms of solutions, emulsions, suspensions, paste, cream, or gel which moves as a fluid so that it may be injected through a needle, cannula, tube, laproscope, probe, or other delivery device.
  • injectable composition When administered to a subject, such injectable composition forms a depot in-situ from which the controlled release of the active agent can be sustained for a desired period of time depending upon the composition.
  • the depot or implant may be a solid, a gel, a paste, a semisolid, or a viscous liquid.
  • the duration of the sustained release of the active substance can be controlled over a period of time from several weeks to one year.
  • the sustained release microspheres can control the active agent over a period of time from several hours to days and several days to weeks and several weeks to months, i.e. till 6 months and meant for at least once weekly or bi weekly administration.
  • the sustained release microspheres are meant for once monthly administration.
  • the sustained release microspheres are meant for once in two months or once in 4 months or once in 6 months administration.
  • a typical release mechanism for these types of microspheres compositions includes three phases that can be generally represented as the initial lag phase (including initial burst release), the erosion phase and plateau phase.
  • the initial burst release typically occurs as soon as the formulation comes in contact with the dissolution medium, till 24 - 72 hours. Thereafter, there is a lag phase where there is further negligible release of drug from the polymer matrix. This phase is primarily governed by diffusion. Erosion phase commences once the polymer molecular weight falls beyond a threshold value due to hydrolysis by dissolution media. The bulk of the drug in the polymer matrix is released during this period. Erosion phase and its onset is very important for any sustained release microspheres as this is governing the time required to get the maximum concentration of the drug, i.e.
  • t max and total time period of drug release Erosion is also influences the maxim concentration of the drug in the body, i.e. C m ax- 80% - 90% weight of the drug is released during this phase.
  • Plateau phase is the final phase wherein the remaining of the drugs gets released from the polymer matrix. The duration of each phase can be modified as per the need of the required release profile, treatment duration and type of the active agent etc.
  • an injectable microsphere composition for sustained release of active agent with a low initial burst comprises: a biodegradable polymer having an acid number of less than or equal to 10 mgKOH/g, an active agent and one or more pharmaceutically acceptable carriers.
  • the biodegradable polymer is lactate based polymer.
  • the lactate based polymer is poly (D, L-lactide-co-glycolide) polymer (PLGA).
  • PLGA polymer is PLGA glucose star polymer.
  • Acid number of the polymer is the "mg” amount of potassium hydroxide required to neutralize the acid present in one gram of the polymer. Polymers with acid ended groups will have some acid number. Lower molecular weight polymers will have more acid ended groups, and will have higher acid numbers. Extractable oligomer acids in polymers may also contribute to the acid number.
  • the acid number of the lactate-based polymers of the present invention is from 0 to 30 mgKOH/g.
  • the lactate-based polymers of the present invention are having an acid number of less than or equal to 20 mgKOH/g, preferably less than or equal to 10 mgKOH/g, more preferably less than or equal to 5 mgKOH/g.
  • the acid number of the polymer is less than or equal to 5 mgKOH/g.
  • the acid number of the polymer is less than or equal to 4 mgKOH/g.
  • the acid number of the polymer is less than or equal to 3 mgKOH/g.
  • the acid number of the polymer is less than or equal to 2 mgKOH/g.
  • the polymer acid number is in between 1 mgKOH/g and 10 mgKOH/g. In another embodiment, the polymer acid number is in between 1 mgKOH/g and 5 mgKOH/g. In another embodiment, the polymer acid number is in between 5 mgKOH/g and 10 mgKOH/g. In preferred embodiment, the polymer acid number is in between 2 mgKOH/g and 5 mgKOH/g. In other preferred embodiment, the polymer acid number is in between 2.5 and 5 mgKOH/g. In other preferred embodiment, the polymer acid number is in between 2.5 and 4.5 mgKOH/g. In other preferred embodiment, the polymer acid number is in between 3 mgKOH/g and 5 mgKOH/g.
  • the polymer acid number is in between 3 and 4.5 mgKOH/g. In other preferred embodiment, the polymer acid number is in between 4 and 5 mgKOH/g. In other preferred embodiment, the polymer acid number is in between 2 and 3 mgKOH/g. In other preferred embodiment, the polymer acid number is in between 2 and 4 mgKOH/g.
  • low initial burst is defined to mean the microspheres release less than or equal to 1 % by weight of a total amount of the active agent within 1 hour at 37° C and pH 4.0 and preferably less than or equal to 0.5% by weight of a total amount of active agent within 1 hr and most preferably less than or equal to 0.2% by weight of a total amount of active agent within 1 hr.
  • the low initial burst can also be characterized by release of less than or equal to 10% by weight of a total amount of the active agent within 1 day at 37° C and pH of 4.0 and preferably less than or equal to 5% by weight of a total amount of the active agent within 1 day at 37° C and pH of 4.0 and most preferably less than or equal to 2% by weight of a total amount of the active agent within 1 day at 37° C and pH of 4.0.
  • active agent is meant to include any materials having diagnostic and/or therapeutic properties including, but not limited to, organic small molecules, inorganic small molecules, macromolecules, peptides, oligopeptides, proteins, or enzymes, nucleotides, nucleosides, oligonucleotides, oligonucleosides, polynucleotides, polynucleotides, polynucleic acids or similar molecules constitute such chemical compounds.
  • Peptides are one of preferred active agents.
  • Non-limiting examples of therapeutic properties are antimetabolic, antifungal, anti inflammatory, antitumoral, antiinfectious, antibiotics, nutrient, agonist, and antagonist properties.
  • active agents of the present invention may be in the form of a free molecule, an organic or inorganic salt of the free molecule, or it may be complexed or covalently conjugated with a carrier agent, may be a pro-drug, or may be a multiform active agent (multiple units of the active agent either complexed or covalently bonded together).
  • peptide as used herein is in a generic sense to include poly(amino acids) that are normally generally referred to as “peptides”, “oligopeptides”, and “polypeptides” or “proteins” which are used interchangeably herein.
  • the term also includes active peptide analogs, derivatives, acylated derivatives, glycosylated derivatives, pegylated derivatives, fusion proteins and the like.
  • peptide is meant to include any active peptides having diagnostic and/or therapeutic properties including, but not limited to, antimetabolic, antifungal, anti-inflammatory, antitumoral, antiinfectious, antibiotics, nutrient, agonist, and antagonist properties.
  • the term also includes synthetic analogues of peptides, unnatural amino acids having basic functionality, or any other form of introduced basicity.
  • the peptide of the present invention contains at least one nucleophilic group.
  • the phrase "at least one" means that the peptide may also contain a multiple number of nucleophilic groups.
  • the active peptides of the invention may include, but are not limited to, oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), prolactin, luteinising hormone, luteinizing hormone releasing hormone (FHRH), FHRH agonists such as euprorelin, buserelin, gonadorelin, deslorelin, fertirelin, histrelin, lutrelin, goserelin, nafarelin, triptorelin, cetrorelix, enfuvirtide, thymosin a abarelix, FHRH antagonists, growth hormones (including human, porcine, and bovine), growth hormone releasing factor, insulin, erythropoietin (including all proteins with erythropoietic activity), somatostatin, glucagon, interleukin (which includes
  • the preferred peptide used herein also includes peptides such as somatostatin, Octreotide, pasireotide, SOM230, and lanreotide.
  • somatostatin includes its analogues or derivatives thereof.
  • Octreotide includes its analogues or derivatives thereof.
  • derivatives and analogues mean branched, straight chain or cyclic polypeptides in which at least one of the amino acids has been omitted or substituted by at least one other amino acid radical(s); and also include at least one functional group being substituted for at least one other functional group(s); and at least one group being substituted by at least one other isosteric group(s).
  • the terms mean all modified derivatives of Octreotide that are biologically active and have a similar effect as unmodified Octreotide.
  • the invention further provides the use of a pharmaceutical composition according to the present invention for inter alia long-term maintenance therapy in acromegalic patients, and treatment of severe diarrhea and flushing associated with malignant carcinoid tumors and vasoactive intestinal peptide tumors (VIPoma tumors).
  • the active agent used in the present invention may be in the form of free base or a pharmaceutically acceptable salt.
  • the acid used to form the pharmaceutically acceptable salt of the active agent preferably has a pKa less than 5.
  • the acids suitable for the present invention may be selected from, but not limited to, the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, chromic acid, sulfuric acid, methanesulfonic acid, trifluromethane sulfonic acid, trichloroacetic acid, dichloroacetic acid, bromoacetic acid, chloroacetic acid, cyanoacetic acid, 2- chloropropanoic acid, 2-oxobutanoic acid, 2-chlorobutanoic acid, 4-cyanobutanoic acid, pamoic acid, perchloric acid, phosphoric acid, hydrogen iodide, acetic acid, 2,2- dichloroacetic acid, adipic acid, alginic acid, L-ascorbic acid,
  • the active agent of the present invention is Octreotide free base or suitable salts or complex thereof.
  • Suitable salts include inorganic or organic acids or polymeric acids. This includes Octreotide acetate. Complexes might be formed by addition of Octreotide and inorganic compounds.
  • the sustained release microspheres of Octreotide acetate is used for the treatment of acromegaly, long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors (Vasoactive Intestinal Peptide Tumors - VIPomas).
  • the amount of the octreotide present in the finished microspheres is lOmg or 20mg or 30 mg.
  • Biodegradable polymers are polymers that are hydrolyzable, and/or bioerode in situ primarily through hydrolysis and/or enzymolysis.
  • biodegradable polymer as used herein is meant to include any biocompatible and/or biodegradable synthetic and natural polymers that can be used in vivo.
  • the biodegradable polymer of the present invention is polyester. These polyesters may be a linear polymer, or a branched or star polymer, or a mixture of a linear polymer and a branched and/or star polymer.
  • the biodegradable polymer of the present invention is lactate-based polymer.
  • polylactide-co-glycolides which are preferably used according to the invention having a molecular weight between 2,000 and 500,000 Daltons.
  • suitable molecular weights generally ranges from about 10,000 to about 200,000 Daltons, more specifically from about 15,000 to about 150,000 Daltons, and most specifically from about 30,000 to about 60,000 Daltons.
  • a variety of lactic acid: glycolic acid ratios are applicable herein, and the ratio is largely a matter of choice, depending in part on the rate of degradation desired.
  • a 50:50 PLGA polymer, containing 50% D,L-lactide and 50% glycolide is a fast resorbing polymer while 75 :25 PLGA degrades more slowly, and 85:15 and 90:10, even more slowly, due to the increased lactide component.
  • a suitable ratio of lactide: glycolide is easily determined by one of skill in the art based on the nature of the disorder to be treated.
  • mixtures of microspheres with varying lactide: glycolide ratios can be employed in the compositions of the disclosure to achieve the desired release kinetics.
  • the biodegradable polymer as per the present invention having the molar ratios of lactide: glycolide is ranges from about 90:10 to 10:90. In another embodiment the said ratio is from 80:20 to 20:80. In a preferred embodiment the molar ratios of lactide: glycolide is ranges from about 75 :25 to 25 :75. In other preferred embodiment the molar ratios of lactide: glycolide is ranges from about, 60:40 to 40:60. The most preferred molar ratio of lactide: glycolide as per the present invention is 55 :45 to 45:55. Another preferred molar ratio of lactide: glycolide as per the present invention is 50:50.
  • the selection of particular monomer ratios of lactic acid to glycolic acid in the polymer can be readily modified by one of ordinary skill in the art as discussed above.
  • the disclosure advantageously use sugar modified PLGA. That is, there are sugar moieties such as glucose bonded to the polymer chain, as there are in the“star polymer” disclosed in U.S. Pat. No. 5,538,739 & GB 2,145,422B and used in Sandostatin LAR.
  • the star polymers preferably have a polydispersity of from 1.7 to 3.0, preferably from 2.0 to 2.5.
  • the intrinsic viscosities of star polymers of M w 35,000 and M w 60,000 are 0.36 and 0.51 dL/g in chloroform respectively.
  • a star polymer having a M w 52,000 has a viscosity of 0.475 dL/g in chloroform.
  • the lactate-based polymer of the present invention includes homopolymers of lactic acid or lactide monomers (poly(lactic acid) or polylactide, PLA), and copolymers of lactic acid (or lactide) with other monomers (for example, glycolic acid (or glycolide) (poly(lactide-co-glycolide), PLG or PLGA) and the like).
  • the lactate-based polymer may have the same end groups, i.e., all the end groups are the same, such as ester, or hydroxyl or carboxylic acid.
  • the lactate-based polymer may have mixed end groups of ester, hydroxyl, and/or carboxylic acid.
  • the lactate -based polymer can have a diol core with end hydroxyl groups.
  • the lactate-based polymer may have a triol or polyol core, such as glucose, with end hydroxyl groups.
  • the lactate-based polymer may have one end group as an ester and the other end with a hydroxyl group or carboxylic acid group.
  • the lactate -based polymer may also have one end hydroxyl group and the other end with a carboxylic acid or an ester, or vice versa.
  • the lactate based polymer having a weight average molecular weight range is between 5,000 - 500,000 Daltons. In a preferred embodiment, the weight average molecular weight of the polymer ranges between 30,000 - 60,000 Daltons. In most preferred embodiment of the present invention, the weight average molecular weight of the polymer is 40,000 - 60,000 Daltons.
  • the lactate based polymer having a residual monomer content of less than or equal to 2.0% by weight. In a preferred embodiment, the residual monomer content is less than or equal to 1.0% by weight. In a most preferred embodiment, the residual monomer content of the polymer is less than or equal to 0.1% by weight
  • the lacate based polymer having an inherent viscosity (IV) in the range of 0.3 - 0.7 dL/g in chloroform. In a preferred embodiment, the IV of the polymer is 0.40 - 0.60 dL/g in chloroform. In another preferred embodiment, the IV of the polymer is 0.42 - 0.52 dL/g in chloroform.
  • IV inherent viscosity
  • injectable microsphere composition for sustained release of Octreotide acetate with a low initial burst comprises: (poly (D, L-lactide-co-glycolide) glucose star polymer (PLGA glucose star polymer) having an acid number of less than or equal to 10 mgKOH/g.
  • injectable microsphere compositions for sustained release of Octreotide acetate with a low initial burst comprises: (poly (D, L-lactide-co-glycolide) glucose star polymer (PLGA glucose star polymer) having an acid number of less than or equal to 10 mgKOH/g, Octreotide acetate and pharmaceutically acceptable carriers.
  • the microspheres compositions of the present invention may contain drug loading in a range of 0.01 to 40% by weight.
  • the drug loading is about 1 to 10% by weight.
  • the drug loading is ranges from 3% to 5% by weight.
  • the optimal drug loading depends upon the period of release desired and the potency of the active substance
  • the drug: polymer ratio in the finished microspheres is ranges about 1 :10 to 1 :30. In a preferred embodiment, the drug: polymer ration is about 1 :15 to 1 :20.
  • the weight % of the polymer in the finished microspheres is about 50% to 90%. In a preferred embodiment, the % of the polymer is about 60% to 80%
  • Another aspect of the present invention describes the process of preparation of the sustained release microspheres with low initial burst of the active agent comprises lactate based polymer with an acid number of less than or equal to 10 mgKOH/g.
  • This process of preparation of sustained release microspheres with low initial burst of the active agent of the present invention is simple, improved, feasible, scalable to commercial scale, commercially economically viable.
  • phase-separation or coacervation technique an aqueous solution of peptide/protein is emulsified or alternatively the peptide/protein is dispersed in solid form into solution containing dichloromethane and PLGA. Silicone oil is added to this dispersion at a defined rate, reducing solubility of polymer in its solvent.
  • the polymer-rich liquid phase (coacervate) encapsulates the dispersed peptide/protein molecules, and embryonic microspheres are subjected to hardening process by means of hardening agent to get the hardened microspheres. Filtering the microspheres and washing the microspheres with suitable solvent to remove the residual solvent followed by drying the microspheres to get the finished microspheres.
  • a polymer is dissolved in a volatile organic solvent such as dichloromethane or acetone.
  • the protein is suspended as solid or emulsified as aqueous solution in this organic solution by homogenization. After that, the resulting dispersion is atomized through a (heated) nozzle into a heated air flow.
  • the organic solvent evaporates, thereby forming microspheres with dimensions of typically 1-100 m.
  • the microspheres are collected in a cyclone separator. For the complete removal of the organic solvent, a vacuum- drying or Lyophilization step can follow downstream.
  • the internal structure of the resulting polymeric microspheres depends on the solubility of the peptide/protein in the polymer before being spray-dried leading to the formation of reservoir or matrix type products.
  • the final product obtained following spray drying is matrix or monolithic type, that is, polymer particles with dissolved or dispersed nature of the active ingredient (defined as microspheres).
  • the product obtained is reservoir type, that is, a distinct polymeric envelope/shell encapsulating a liquid core of dissolved active ingredient (defined as microcapsules)
  • Oil-in- water (o/w) and water- in-oil- water (w/o/w) are the two hydrous techniques representing, respectively the single and double emulsion formation during microspheres preparation.
  • peptides/proteins are dissolved in an organic solvent (e.g., alcohol) or in an aqueous solution and then mixed or emulsified with an organic solution (non-miscible with water) of the polymer to form a solution or water-in-oil (w/o) emulsion, respectively.
  • Dichloromethane serves as organic solvent for the PLGA and the o/w primary emulsion is formed using either high-shear homogenization or ultrasonication.
  • This primary emulsion is then rapidly transferred to an excess of aqueous medium containing a stabilizer, usually polyvinyl alcohol (PVA). Again homogenization or intensive stirring is necessary to initially form a double emulsion of w/o/w. Subsequent removal (by evaporation) of organic solvent by heat, vacuum, or both results in phase separation of polymer and core to produce microspheres. Instead of solvent evaporation, solvent extraction with large quantity of water with or without a stabilizer can also be undertaken to yield microspheres containing peptide/protein.
  • PVA polyvinyl alcohol
  • the microspheres of the present invention are prepared by Phase separation technique (Co-acervation phase separation).
  • a process for preparing microspheres for sustained release of an active agent with a low initial burst comprises:
  • a process for preparing microspheres for sustained release of Octreotide acetate with a low initial burst comprises:
  • the suitable solvent for the active agent dissolution is polar solvent.
  • the polar solvent is an alcoholic solvent.
  • the alcoholic solvents are methanol, ethanol or combination thereof.
  • the concentration (in % weight) of the alcoholic solvent in the drug polymer combined phase is less than about 10%.
  • a method for preparing sustained release microspheres with low initial burst of the active agent comprises:
  • a method for preparing sustained release microspheres with low initial burst of the Octreotide acetate comprises:
  • a method for preparing sustained release microspheres with low initial burst of the active agent comprises:
  • active agent is dissolved in alcoholic solvent to form drug solution
  • microsphere suspension e) mixing with hardening agent to the co-acervates to form a microsphere suspension f) filtering microspheres followed by washing and drying of microspheres to get the finished microspheres.
  • a method for preparing sustained release microspheres with low initial burst of the Octreotide acetate comprises:
  • microsphere suspension e) mixing with heptane to the co-acervates to form a microsphere suspension f) filtering microspheres followed by washing and drying of microspheres to get the finished microspheres.
  • the said Octreotide solution is prepared by dissolving the Octreotide acetate in Methanol solvent. In another embodiment the said Octreotide solution is prepared by dissolving the Octreotide acetate in Ethanol solvent. In another embodiment the said Octreotide solution is prepared by dissolving the Octreotide acetate in combination of ethanol and methanol solvent.
  • the concentration of alcoholic solvent is less than about 9% or less than about 8% or less than about 7% or less than about 6 % or less than about 5% or less than about 4% or less than about 3% or less than about 2% or less than about 1%.
  • the concentration of ethanol or methanol is less than about 5%.
  • the ethanol or methanol concentration in the drug-polymer combined phase is less than about 4%, preferably less than about 3%, more preferably less than about 2%, most preferably less than about 1%.
  • Suitable solvents for the polymer matrix material include but not limited to Dichloromethane, Chloroform, Benzene, Ethyl acetate, Benzyl alcohol, THF, Acetone, dimethyl sulfoxide (DMSO), dime thy lformamide, dimethyl acetamide, dioxane, tetrahydrofuran (THF), acetonitrile, methylene chloride, ethylene chloride, carbon tetrachloride, chloroform, lower alkyl ethers such as diethyl ether and methyl ethyl ether, hexane, cyclohexane, benzene, acetone, ethyl acetate, and the like.
  • the weight % of the polymer in the polymer solution is less than 10%.
  • the % weight of active agent in the drug solution is less than 20%.
  • the concentration of the said polymer in the drug polymer combined phase ranges from about 2% to about 15% by weight, in a preferred embodiment, the said concentration ranges about 3 % to about 10% by weight.
  • the concentration of said Active agent in the drug-polymer combined phase ranges from 0.1% to about 5% by weight and with a preferable range of from 0.1% to 1% by weight.
  • the drug: polymer ratio in the drug polymer combined phase is ranges about 1 :5 to about 1 :50. In a preferred embodiment, the ratio is about 1 :10 to 1 :20
  • phase inducers are solvents which are miscible with the polymer-drug mixture, and cause the embryonic microcapsules to form prior to hardening; silicon oils, natural and mineral oils & triglycerides are used as a phase inducer. Silicone oils are the preferred phase inducers.
  • the ratio of the polymer solvent (DCM): phase inducers (silicon oil) are 1 :5 to 5 : 1.
  • a suitable hardening agent which is a non-solvent for the polymer, while it is miscible with polymer solvent and silicone oil, it extracts both, eventually hardening the microspheres.
  • Suitable hardening agents of the present invention are single solvent system or combination of solvents. Heptane, hexane or higher alkanes are preferred hardening solvents. Combination of the solvents, i.e. heptane with alcoholic solvents like methanol or ethanol may be used as hardening agents.
  • the ratio of the polymer to hardening solvent ranges from 1 :50 to 1 :250, a preferred range of the same are 1 :200.
  • Residual solvents are removed from the microspheres by washing step. Multiple washings were performed until to get the desired limit of the residual solvent level. Single solvent system or combination of the solvent systems used for the washing. Different washing solvents used in the present invention includes but not limited to Heptane, Hexane, ethanol, water or buffered heptane, or any combinations thereof. A little quantity of the surfactant for example span-80 may be used along with washing solvent to aid the dispersibility or wetting of the suspension and to avoid the aggregation of the microspheres. The weight % of the surfactant in the washing solvent ranges from 0.01% to 1 %.
  • the microspheres of the invention may be dried, e.g. to remove residual solvents, especially volatiles like dichloromethane etc. Dryers used according to the present inventions are vacuum dryer or freeze dryer. In another aspect, in the drying step, the microspheres of the present invention may be subjected to 1) a freeze-drying process or 2) vacuum drying at 50 to KG 2 millibars, e.g.
  • drying is done under vacuum in vacuum dryer at a loading temperature of -5°C to 5°C for a period of 12-24hrs and ramping to a temperature of 25°C to 50°C for a period of 12 - 24 hrs. and plateau drying at a temperature of up to about 50°C for a period of 12 - 48 hrs.
  • the microspheres of the invention may be purged with nitrogen or another inert gas.
  • the microparticles of the invention may be heated, e.g. from 25 to 55° C., preferably from 48 to 54° C. Duration of the drying period may be, e.g. from 2 hours to 5 days.
  • the resultant microspheres may be free-flowing powders of spherical particles.
  • the microspheres contain less than 2000 ppm of DCM. According to another embodiment of the present invention, the microspheres contain less than 2000 ppm of ethanol. According to other embodiment of the present invention, the microspheres contain less than 20,000 ppm of heptane.
  • microparticles according to the present invention may be mixed or coated with an anti agglomerating agent or covered by a layer of an anti-agglomerating agent, e.g. in a prefilled syringe or vial.
  • Suitable anti-agglomerating agents include, e.g. mannitol, glucose, dextrose, sucrose, lactose, trehalose, glycine, sodium chloride, or water-soluble polymers such as polyvinylpyrrolidone or polyethylene glycol.
  • an anti-agglomerating agent is present in an amount of about 0.1 to about 20%, preferentially about 10% to 20%, e.g.
  • a preferred anti-agglomerating agent in this respect is mannitol.
  • an anti-agglomerating agent can be applied to the microparticles during their manufacturing process. For example, at the step of filtering/washing the microparticles they can be additionally rinsed with an aqueous solution of an anti-agglomerating agent. Thus, a layer of the anti-agglomerating agent is formed on the surface of the microparticles.
  • the anti-agglomerating agent is present in the microparticles at an amount of less than 20%, more preferably it is less than 18% by weight of the microparticles.
  • a preferred anti- agglomerating agent in this respect is mannitol.
  • the particle size of the microspheres ranges from 1 to 250 microns, preferably 10 to 200 microns, most preferably 10 to 130 microns in diameter.
  • the D50 of the microspheres ranges from 10 to 200 microns, preferably 20 to 150 microns.
  • the microspheres of the present invention can be administered as a suitable pharmaceutical composition.
  • the microspheres can be administered alone, or in appropriate combination with other active agents or drug therapies, as part of a pharmaceutical composition.
  • These pharmaceutical compositions may include the microspheres in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art.
  • the compositions should be sterile and contain a therapeutically effective amount of the microsphere in a unit of weight or volume suitable for administration to a patient.
  • pharmaceutically-acceptable carrier as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human or other mammal.
  • carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient-containing microspheres are combined to facilitate the application.
  • the components of the pharmaceutical composition are capable of being co-mingled with the components of the present disclosure (e.g., the active agent, the biodegradable polymer), and with each other, in a manner such that there is no interaction that substantially impairs the desired pharmaceutical efficacy.
  • Pharmaceutically acceptable carrier further means a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier depend on the route of administration.
  • Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, desiccants, bulking agents, propellants, acidifying agents, coating agents, solubilizers, and other materials which are well known in the art.
  • Pharmaceutically acceptable carriers suitable for oral, subcutaneous, intravenous, intramuscular, or other type of administrations also are well known, and can be found, e.g., in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), as well as in other sources.
  • The“pharmaceutically-acceptable carrier” according to the disclosure can be bulking agents and wetting agents, for example, sodium carboxymethylcellulose and mannitol.
  • the amount of mannitol in the microspheres composition ranges from 10% to 50%, even more preferably about 18% to about 21% by weight of the microsphere composition.
  • the pharmaceutical composition according to the present invention containing microparticles may also contain a vehicle to facilitate reconstitution.
  • a vehicle Prior to administration, the microparticles are suspended in a suitable vehicle for injection.
  • the suitable quantity of vehicle used for reconstitution is ranges from 1ml to 5ml, preferably 2 ml to 2.5 ml.
  • said vehicle is water based containing pharmaceutical excipients such as mannitol, sodium chloride, glucose, dextrose, sucrose, or glycerins, non-ionic surfactants (e.g.
  • poloxamers for example poloxamer 188, poly(oxyethylene)-sorbitan-fatty acid esters), carboxymethylcellulose sodium (CMC-Na), sorbitol, poly(vinylpyrrolidone), or aluminium monostearate in order to ensure isotonicity and to improve the wettability and sedimentation properties of the microparticles.
  • the wetting and viscosity enhancing agents may be present in an amount of 0.01 to 10% preferably about 0.5% to about 5% by weight in the pharmaceutical composition; the isotonicity agents are added in a suitable amount to ensure an isotonic injectable suspension.
  • the viscosity of the diluent ranges from lcps to 20,000 cps, preferably lcps to 20cps.
  • the invention further provides a kit comprising the depot formulation in a vial, optionally equipped with a transfer set, together with a water-based vehicle in an ampoule, vial or prefilled syringe or as microparticles and vehicle separated in a double chamber syringe.
  • the pharmaceutically acceptable carrier comprises an anti-agglomerating agent, viscosity enhancing agent, surfactant and diluent
  • the pharmaceutically acceptable carrier comprises mannitol, sodium CMC, Poloxamer 188 and water for injection.
  • Sustained release microspheres of the present invention are administered by IM or SC administration.
  • microspheres of the present invention are administered by IM administration.
  • Microspheres of the present invention are filled in to the vials or ampoules, and these microspheres are to be added to vehicle before administration. These microspheres when injected, delivers active agent for a period of one day or a week or one month or 6 months.
  • the microspheres of the present invention deliver the active agent for a period of one month. In further embodiments, less than or equal to 10% of the active agent is released within 3 days. In another embodiment, less than or equal to 20% of the active agent is released within 15 days. In another embodiment, greater than or equal to 60% of the active agent is released within 23 days. In another embodiment, greater than or equal to 80% of the active agent is released within 30 days. In further embodiment, the onset of the erosion phase is approx 15 th day to 23 th day. Still further embodiment of the present invention, onset of the erosion phase is approx. 17 th day to 20 th day.
  • Octreotide microspheres is used for the treatment of acromegaly, long term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors (Vasoactive Intestinal Peptide Tumors - VIPomas).
  • Octreotide acetate solution is prepared by addition of approx. 450 mg of Octreotide acetate in suitable quantity of ethanol or methanol.
  • Polymer solution is prepared by addition of 6gm of poly(D,L-lactide-co-glycolide)glucose (PLGA glucose polymer) in approx. 100 gm of DCM. (55:45 molar ratio of lactide to glycolide, Mw approx. 45,000 to 55,000 Daltons, acid number of 2- 5).
  • Phase separation was affected by adding approx. 150 ml of silicon oil (350 cs) to the drug-polymer combined phase to form co-acervates.
  • the resultant mixture was added to a stirred solution of approx.1000 gm of n-heptane, after stirring for 10 to 30 minutes, the microspheres were collected by vacuum filtration.
  • microspheres were washed with sequence of solvent systems, i.e. stirring with 500 ml of n-heptane, followed by approx. 500 ml of ethanol, optionally containing 1 ml of Span 80 and final washing done with 500 ml of n-heptane. Finally, the microspheres were collected by vacuum filtration and dried at suitable temperature conditions of -5°C to 45°C for 3-5 days. The residual DCM and ethanol level of these microspheres was less than 2000 ppm
  • Microspheres were prepared in the same manner as described in example 1 , with a difference in the acid number, type pf solvent which are given below Table 1
  • Microspheres were prepared in the same manner as described in example 1 , with a difference in concentration of polar solvent and acid number
  • IVR In-vitro release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des microsphères à libération prolongée à faible éclatement initial de l'agent actif et un processus spécifique de préparation de telles compositions. En particulier, la présente invention concerne des microsphères à libération prolongée de l'octréotide ou de ses sels pharmaceutiquement acceptables à faible éclatement initial, comprenant un polymère poly (D, L-lactide-co-glycolide) et son processus de préparation.
PCT/IB2019/050987 2018-02-07 2019-02-07 Microsphères à libération prolongée à faible éclatement initial et leurs procédés de préparation WO2019155396A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841004614 2018-02-07
IN201841004614 2018-02-07

Publications (1)

Publication Number Publication Date
WO2019155396A1 true WO2019155396A1 (fr) 2019-08-15

Family

ID=67549332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/050987 WO2019155396A1 (fr) 2018-02-07 2019-02-07 Microsphères à libération prolongée à faible éclatement initial et leurs procédés de préparation

Country Status (1)

Country Link
WO (1) WO2019155396A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000017191A1 (it) * 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
WO2022226534A3 (fr) * 2021-04-23 2023-01-26 Oakwood Laboratories, Llc Formulations de microsphères comprenant de multiples peptides non identiques et leurs procédés de fabrication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045633A2 (fr) * 2002-11-19 2004-06-03 Novartis Ag Composition pharmaceutique comprenant des microparticules
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045633A2 (fr) * 2002-11-19 2004-06-03 Novartis Ag Composition pharmaceutique comprenant des microparticules
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000017191A1 (it) * 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
WO2022013233A1 (fr) * 2020-07-15 2022-01-20 Xbrane Biopharma Ab Processus sans eau pour la préparation d'une composition pharmaceutique destinée à une libération plus soutenue et commandée de la taxréline ou d'un sel de celle-ci
WO2022226534A3 (fr) * 2021-04-23 2023-01-26 Oakwood Laboratories, Llc Formulations de microsphères comprenant de multiples peptides non identiques et leurs procédés de fabrication

Similar Documents

Publication Publication Date Title
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
JP5053846B2 (ja) 生物活性化合物の制御放出送達用医薬組成物
KR101245919B1 (ko) 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제
WO1993015722A1 (fr) Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
US20190209462A1 (en) Octreotide depot formulation with constantly high exposure levels
IE902435A1 (en) Processes for the preparation of sustained release formulations of water soluble peptides
EP1686964B1 (fr) Composition pharmaceutique
US20100086596A1 (en) Microspheres for releasing an octreotide compound without an initial time lag
WO2011087496A1 (fr) Microsphères pour la libération prolongée d'octréotide sans retard initial
WO2019155396A1 (fr) Microsphères à libération prolongée à faible éclatement initial et leurs procédés de préparation
US20100266704A1 (en) Octreotide depot formulation with constantly high exposure levels
WO2009095450A1 (fr) Préparation à libération soutenue comprenant de l'octréotide et trois polymères linéaires polylactide-co-glycolide
AU2007263004A1 (en) Sustained release formulations of aromatase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19750479

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19750479

Country of ref document: EP

Kind code of ref document: A1